COR2ED Medical Education: Prof. Karin Fijnvandraat, Professor of Paediatric Haematology at the University of Amsterdam in the Netherlands and Dr. Maria Elisa Mancuso, Senior Consultant in Haematology at IRCCS Humanitas Research Hospital in Milan, Italy, have an interesting discussion about prophylaxis in children with haemophilia. Along with five other members of the European Collaborative Haemophilia Network, Prof. Fijnvandraat and Dr. Mancuso recently published a white paper on prophylaxis in children in an evolving treatment landscape, in the journal Haemophilia.
In this podcast episode the two experts discuss when they start prophylaxis in young children, how they choose between plasma-derived and recombinant products and how they select the right treatment regimen, as well as practical aspects of starting prophylaxis, including the importance of involving parents in the decision-making process.
Thrombophilia: Clinical overview and impact on patients What do you know about thrombophilia? Is it acquired or inherited, and what is the impact on...
Extended anticoagulation beyond the initial 3 months is indicated for all types of VTE, except in surgery-or trauma-VTE or in patients at high risk...